Skip to main content

Table 5 Logistic regression analyses for macroalbuminuria

From: Low circulating arachidonic acid is associated with macroalbuminuria in diabetic patients: a cross-sectional examination of the KAMOGAWA-DM cohort study

 

Model 1

Model 2

Model 3

Odds ratio (95% CI)

p-value

Odds ratio (95% CI)

p-value

Odds ratio (95% CI)

p-value

Age, yrs

1.07 (1.03–1.13)

<  0.001

1.06 (1.01–1.12)

0.015

1.03 (0.94–1.13)

0.509

Men

4.43 (1.70–11.5)

<  0.001

3.38 (1.23–9.32)

0.019

4.73 (0.47–47.5)

0.186

Disease duration, yrs

1.06 (1.01–1.10)

0.010

–

–

1.08 (0.96–1.22)

0.180

Body mass index, kg/m2

0.99 (0.91–1.09)

0.878

–

–

1.05 (0.83–1.32)

0.684

20/(fasting C-peptide × fasting plasma glucose)

0.99 (0.93–1.06)

0.596

–

–

1.03 (0.82–1.29)

0.790

Creatinine, μmol/L

1.07 (1.04–1.09)

<  0.001

–

–

1.07 (1.02–1.15)

< 0.001

Total cholesterol, mmol/L

0.81 (0.54–1.21)

0.311

  

1.05 (0.40–2.74)

0.921

Systolic blood pressure, mmHg

1.03 (1.01–1.05)

0.003

–

–

1.02 (0.96–1.08)

0.590

Never smoker

1.00 (Reference)

–

–

–

1.00 (Reference)

–

Ex-smoker

2.90 (1.02–8.22)

0.045

–

–

0.96 (0.11–8.13)

0.974

Current smoker

3.01 (1.14–7.91)

0.026

–

–

2.54 (0.31–20.6)

0.381

Exercise

0.76 (0.33–1.76)

0.527

–

–

0.38 (0.07–1.96)

0.248

Total Energy, kcal/day

1.00 (0.99–1.00)

0.095

–

–

0.99 (0.99–1.00)

0.431

RAS inhibitors

4.85 (1.98–11.87)

<  0.001

–

–

5.04 (0.92–27.6)

0.062

History of CVD

7.57 (2.02–28.4)

0.004

  

1.52 (0.02–99.7)

0.844

Log arachidonic acid

0.03 (0.01–0.21)

<  0.001

0.46 (0.24–0.87)

0.016

0.32 (0.10–0.99)

0.042

  1. Model 1 was univariate; Model 2: adjusted for age, sex; Model 3: model 2 plus body mass index, disease duration, 20/(fasting C-peptide × fasting plasma glucose), uric acids, total cholesterol, systolic blood pressure, smoking status, physical activity, total energy, RAS inhibitors usage, and history of CVD
  2. CVD cardiovascular disease, RAS renin-angiotensin system, UAE urinary albumin excretion